Evidence map›Paper›PMID 42138313›Full record

Trial reportHealth technology assessment (Winchester, England)2026

Effects and costs of a group-based educational intervention to reduce opioid use in people with chronic pain: I-WOTCH RCT.

Harbinder K Sandhu, Katie Booth, Sheeja Manchira Krishnan, Charles Abraham, Sharisse Alleyne, Shyam Balasubramanian, Lauren Betteley, Tom Bromilow, Dawn Carnes, Andrea D Furlan and 20 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Health technology assessment (Winchester, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Harbinder K SandhuWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0003-1522-8078
Katie BoothWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-8530-2566
Sheeja Manchira KrishnanDepartment of Health Sciences, University of York, York, UK.ORCID 0000-0001-8574-695X
Charles AbrahamSchool of Psychology, Deakin University, Geelong, Australia.ORCID 0000-0002-0901-1975
Sharisse AlleyneWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-8026-1176
Shyam BalasubramanianDepartment of Anaesthesia and Pain Medicine, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.ORCID 0000-0001-5149-3595
Lauren BetteleyWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0009-0007-6072-2581
Tom BromilowYork Health Economics Consortium, University of York, York, UK.ORCID 0000-0003-2494-5685
Dawn CarnesWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-3152-3133
Andrea D FurlanToronto Rehabilitation Institute, University Health Network, Toronto, Canada.ORCID 0000-0001-6138-8510
Vijay S GcCentre for Health Economics, University of York, York, UK.ORCID 0000-0003-0365-2605
Kirstie L HaywoodDivision of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-5405-187X
Maddy HillWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0009-0007-4691-5416
Cynthia P Iglesias-UrrutiaDepartment of Health Sciences, University of York, York, UK.ORCID 0000-0002-3426-0930
Ranjit LallWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0003-1737-2866
Andrea MancaCentre for Health Economics, University of York, York, UK.ORCID 0000-0001-8342-8421
Dipesh MistryWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-0875-9260
Joe We MossYork Health Economics Consortium, University of York, York, UK.ORCID 0000-0002-1866-9752
Sian NewtonWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0001-8035-0411
Vivien P NicholsWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-3372-1395
Jennifer NoyesDepartment of Pain Medicine, James Cook University Hospital, Middlesbrough, UK.ORCID 0009-0003-4005-1267
Emma PadfieldWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0003-4832-9609
Anisur RahmanCentre for Rheumatology Research, University College London, London, UK.ORCID 0000-0003-2346-4484
Kate SeersDivision of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0001-7921-552X
Jane ShawDepartment of Pain Medicine, James Cook University Hospital, Middlesbrough, UK.
Nicole Ky TangDepartment of Psychology, University of Warwick, Coventry, UK.ORCID 0000-0001-7836-9965
Stephanie Jc TaylorWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0001-7454-6354
Colin TysallUniversity/User Teaching and Research Action Partnership, University of Warwick, Coventry, UK.ORCID 0000-0001-5109-3989
Martin UnderwoodWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID 0000-0002-0309-1708
Sam EldabeDepartment of Pain Medicine, James Cook University Hospital, Middlesbrough, UK.ORCID 0000-0002-9250-1886

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The long-term use of strong opioids for chronic non-cancer pain puts people at risk of serious harm. Objectives: To test the effectiveness and cost-effectiveness of a multicomponent intervention targeting opioid use for the treatment of chronic pain. Design: A multicentred randomised controlled trial with embedded process evaluation. Setting: Primary care. Participants: Adults using strong opioids for non-malignant chronic. Interventions: Participants were randomised 1 : 1 (using a minimisation programme stratified by geographical locality, baseline pain intensity score and baseline morphine equivalent dose) to either usual care (an educational booklet and relaxation compact disc) or usual care plus the I-WOTCH intervention; 3 day-long group sessions delivered by a nurse and lay facilitator, plus a one-to-one session and ongoing telephone contact from the nurse to support opioid tapering. Main outcome measures: The two primary outcomes were Patient-Reported Outcomes Measurement Information System Pain Interference Short Form (8A), and proportion using no opioids, at 12 months. Results: We randomised 608 people. At 12 months, there was no between-group difference in Patient-Reported Outcomes Measurement Information System Pain Interference Short Form (8A) scores; mean difference, -0.52 (95% confidence interval -1.94 to 0.89). At 12 months, 65/225 (29%) of people in the intervention group and 15/208 (7%) of people in usual-care group reported using no opioids [odds ratio 5.55 (95% confidence interval 2.80 to 10.99)], absolute difference, 21.7% (95% confidence interval 14.8 to 28.6). Over a lifetime horizon, I-WOTCH is on average associated with an incremental cost of £9277 per person, and provides an additional 0.314 quality-adjusted life-years. The deterministic incremental cost per quality-adjusted life-year gained was £29,543. The I-WOTCH intervention may be cost-effective compared to best usual care. The process evaluation suggested group support and shared experience were important to those trying to taper. Limitations: The opioid use analysis is based solely on participant self-report. The findings only apply to people willing to consider opioid reduction and may not apply to a more complex secondary care population. The results may not be applicable to people using very high opioid doses. Conclusions: The I-WOTCH intervention helps substantially more people stop opioids than best usual care without adversely affecting pain interference. Future work: The I-WOTCH intervention should be tested in different healthcare settings and other populations. Trial registration: This trial is registered as Current Controlled Trials ISRCTN49470934. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 14/224/04) and is published in full in

Indexed as

Analgesics, OpioidChronic PainPatient Education as TopicAdultAgedCost-Benefit AnalysisCost-Effectiveness AnalysisFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresPrimary Health CareAnalgesics, OpioidANALGESICSCHRONIC PAINOPIOIDOPIOID-RELATED DISORDERSRANDOMISED CONTROLLED TRIALSELF-MANAGEMENT

Identifiers

PMID42138313
PMCPMC13200030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.